Check for updates

OPEN ACCESS

EDITED BY Caio Pinho Fernandes, Universidade Federal do Amapá, Brazil

REVIEWED BY

Nilufer Orhan, Independent Researcher, Austin, TX, United States Ya-Nan He, Chengdu University of Traditional Chinese Medicine, China

*CORRESPONDENCE Xinke Zhao, ⊠ zxkd412@163.com Yingdong Li, ⊠ lydj412@163.com

[†]These authors have contributed equally to this work

RECEIVED 08 December 2022 ACCEPTED 10 April 2023 PUBLISHED 28 August 2023

CITATION

Gao X, Ren C, Li L, Zhao H, Liu K, Zhuang M, Lv X, Zhi X, Jiang H, Chen Q, Zhao X and Li Y (2023), Pharmacological action of *Hedysarum* polysaccharides: a review. *Front. Pharmacol.* 14:1119224. doi: 10.3389/fphar.2023.1119224

COPYRIGHT

© 2023 Gao, Ren, Li, Zhao, Liu, Zhuang, Lv, Zhi, Jiang, Chen, Zhao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Pharmacological action of *Hedysarum* polysaccharides: a review

Xiang Gao^{1,2,3,4†}, Chunzhen Ren^{1,2,3†}, Linyu Li^{2,3,5†}, Huilin Zhao^{1,2,3}, Kai Liu^{1,2,3}, Mengjie Zhuang⁶, Xinfang Lv^{1,2,3,4}, Xiaodong Zhi^{1,2,3,4}, Hugang Jiang^{1,2,3}, Qilin Chen^{1,2,3}, Xinke Zhao^{1,2,3,4*} and Yingdong Li^{1,2,3*}

¹School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, China, ²Gansu Province Key Laboratory of Chinese Medicine for the Prevention and Treatment of Chronic Diseases, Lanzhou, China, ³Key Clinical Specialty of the National Health Commission of the People's Republic of China, Key Specialized Cardiovascular Laboratory National Administration of Traditional Chinese Medicine, Lanzhou, China, ⁴Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China, ⁵First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, China, ⁶Xinjiang Medical University School of Basic Medicine, Urumqi, China

Hedysarum, a traditional Chinese herbal medicine and food with a long history of clinical application, is used to improve health conditions and treat various diseases. Hedysarum polysaccharides (HPS), flavonoids, saponins, and alkaloids, are the primary components of Hedysarum. HPS is the most important natural active ingredient of Hedysarum, which has many pharmacological effects. Currently, HPS exhibits significant promise in drug development for various ailments such as tumors, diabetes, cardiovascular diseases, Alzheimer's disease, and fibrosis. This review paper discusses the extraction, separation, and content determination techniques of HPS, along with the investigation of its chemical constituents. More importantly, we reviewed the anti-inflammatory pharmacological effects of HPS, such as inhibition of inflammatory factors and NF-κB signaling pathway; antitumor activity through apoptosis induction in tumor cells and blocking tumor cell proliferation and metastasis; antioxidant effects; regulation of various cytokines and immune cells; regulation of blood sugar levels, such as in type I and type II diabetes and in diabetic complications; improvement in symptoms of Alzheimer disease; anti-aging and anti-fibrosis properties; and improvement in cerebral ischemia-reperfusion injury. This review paper establishes the theoretical foundation for future studies on the structure, mechanism, and clinical use of HPS.

KEYWORDS

 HPS , anti-inflammatory, complications of diabetes, anti-tumor, traditional Chinese medicine

1 Introduction

Hedysarum polybotrys Hand.-Mazz. is a plant that belongs to the family Leguminosae. It invigorates the qi and aids the ascending yang, stops sweating, induces diuresis and relieves swelling, promotes salivation and flow of nourishing blood, relieves arthralgia, and supports the expulsion of poison and pus (China Pharmacopoeia, 2020). HPS is the main active component of *Hedysarum*, a traditional Chinese medicine (TCM), which is extracted from the dried root of *Hedysarum* and contains active polysaccharides (Qiang et al., 2018). It has several pharmacological effects, such as anti-tumor, anti-aging, immune enhancement, and

anti-inflammatory properties (Jia et al., 2020; Feng et al., 2021). In recent years, several studies have compared HPS with *Astragalus* polysaccharide (APS) and have discovered that HPS is more effective than APS in terms of immunomodulation and antioxidation (Bai et al., 2020). HPS is widely used because of its advantages of low toxicity, no residue (easy to be absorbed by the body), non-tolerance (the body's responsiveness to the drug does not decrease after repeated administration). As a result, the utilization of HPS is gaining more attention from scholars worldwide. This paper provides an overview of the current research on the extraction, isolation, and pharmacological effects of HPS. Additionally, it analyzes and summarizes the potential value of HPS, thus, serving as a reference for further research on HPS and its application in the fields of food, health products, and pharmaceuticals.

2 Extraction and content determination of HPS

2.1 Extraction of HPS

Based on their characteristics, polysaccharides are commonly extracted using chemical methods such as water, acid, and alkali extraction, physical methods such as microwave and ultrasonic extraction, and biological methods such as enzyme extraction. Traditional water extraction and alcohol precipitation, enzymatic, and ultrasonic extraction methods have been primarily detailed in the literature.

2.1.1 Water extraction and alcohol precipitation method

Water extraction and alcohol precipitation is a traditional HPS extraction method and is also the most widely used. Ma (2008) adopted the orthogonal experimental design to obtain the optimal extraction of crude polysaccharide from Hedysarum rubra by considering the ethanol soaking time, the ethanol reflux time, the medicinal materials-to-concentrated solution ratio as an index, and 70% ethanol-precipitated HPS content in a crude product as an index. The process involved soaking medicinal materials in ethanol for 12 h and then refluxing with ethanol for 1 h to achieve a volume ratio of 1:2 between the medicinal materials and concentrated solution. The ideal temperature and duration for the two-step water extraction and alcohol precipitation process of HPS were found to be 60°C and 1 h, respectively, as reported by Yuan et al. (2015) considered the amount of water added, warm soaking time, warm soaking temperature, and extraction time as the orthogonal test factors, the HPS yield, and the free radical scavenging rate of 1,1-Diphenyl-2-picrylhydrazyl (DPPH), which can reach 0.83%, as the indexes. After a comprehensive evaluation, the optimum water extraction and alcohol precipitation process of HPS was obtained at a temperature of 70°C, performed twice in 15 times the water volume for 3 h with alcohol.

2.1.2 Microwave-assisted extraction

Liu et al. (2007) investigated the extraction of HPS using microwave-ultrasonic technology and compared it to the traditional extraction methods. The results demonstrated that the traditional approach produced a polysaccharide content of 4.19%, whereas the microwave-ultrasonic process resulted in a significantly higher concentration of 8.98%. Additionally, Zhao B. et al. (2015) employed a microwave-assisted technique to extract HPS and utilized a response surface methodology to optimize the process. The optimal extraction conditions included a 45-minute extraction period, 213 W of microwave power, 80°C, a liquid-to-material ratio of 26 to 1, and a 1-hour extraction period. Under these conditions, the HPS yield reached ~10.11%.

2.1.3 Enzymatic hydrolysis

Tan (2010) considered enzyme dosage, enzymolysis temperature, and time as orthogonal factors, with the optimum technological conditions for enzymatic extraction of HPS cellulose being: enzyme dosage of 0.3%, enzymolysis temperature of 40°C and enzymolysis time of 110 min. Wei et al. (2014), based on a uniform design and single-factor experiment, considered enzyme amount, enzymolysis time, extraction time, and water amount as experimental factors, with the HPS extraction rate and total saponins content as indexes. They optimized the enzymatic extraction process of Radix *Hedysarum* by using the quadratic general rotation combination design as indicated below: 280 mg of enzyme, 90 min of enzymolysis, water amount at 21 times, and 180 min of extraction. Enzymatic hydrolysis, a biological extraction method, has considerable development prospects because of its high specificity, small dosage requirement, and little chemical pollution.

In summary, the extraction methods, conditions, and yield of HPS are shown in Table 1.

2.2 Separation of HPS

Currently, there are limited studies on the separation methods of HPS. Madan (Ma, 2008) employed the step alcohol precipitation method to isolate polysaccharides 1, 2, and 3, which were further separated into two parts through gel column chromatography. Gas chromatography analysis showed that these three polysaccharides contained five monosaccharides: rhamnose, arabinose, xylose, glucose, and galactose. Yang Tao (Chen et al., 2012) obtained Hedysarum Polysaccharide 1 (HPS1) from Hongqi using water extraction and 30% ethanol precipitation which was then purified to yield four uniform components. Similarly, Chen Tongqiang et al. (Hui et al., 2010) conducted a series of separation and purification processes on Hedysarum polysaccharide 3 (HPS3) to isolate four uniform components, namely HPS3-A, HPS3-B, HPS3-C, and HPS3-D. Thin layer chromatography and gas chromatography analysis revealed that HPS3-A primarily consisted of glucose, while HPS3-B, HPS3-C, and HPS3-D were composed mainly of arabinose and galactose. Furthermore, Hui He Ping (Yu et al., 2005) reported the deproteinization of crude polysaccharide of Hedysarum membranaceus through the trichloroacetic acid n-butanol method, followed by purification using Sephadex G-25 column chromatography, to obtain a uniform component of Hedysarum membranaceus polysaccharide 2 (HPS2). HPS is a heteropolysaccharide composed of various types and numbers of monosaccharides, resulting in different HPS structures. Presently, research on the separation of HPS is progressing.

Solvent extraction	Liquid to material ratio (g/mL)	Solvent	Extraction times	Extraction time (min)	Free radical scavenging rate	Extraction temperature (°C)	Extraction frequency (kHz)or power (W)	HPS yield (mg/100 g)	Refrences
Water extraction	1:15	70% ethanol	2	60	0.83%	60	-	10.11	Ma, 2008; Yuan et al. (2015)
alcohol precipitation	1:2	-	2	60	-	60	-	-	Ma, 2008; Yuan et al. (2015)
Microwave- assisted extraction	1:26	-	2	60	-	80	213	10.11	Liu et al. (2007), Zhao B. et al. (2015)
Enzymatic hydrolysis	1:21	-	2	110	-	40	-	-	Tan, 2010; Wei et al. (2014)

TABLE 1 The extraction methods, conditions, and yield of HPS.

2.3 HPS content determination method

At present, HPS content is primarily determined through phenolsulfuric acid colorimetry. Here, the sulfuric acid rapidly decomposes the polysaccharide to produce monosaccharide and then dehydrates it to produce sugar aldehyde derivatives so that its content can be determined by colorimetry. Research shows that this method is simple, sensitive, accurate, and reliable with good reproducibility (Wei et al., 2013; Yang and Li, 2013). Wei Shuchang et al. (Chen et al., 2012) adopted the improved differential phenol-sulfur method to quantitatively determine the crude polysaccharide content of Hedysarum stilbene, with glucose being the reference substance. Ouyang Yihua et al. (Ouyang and Yan, 2013) used anthrone-sulfuric acid spectrophotometry to determine HPS content and obtained satisfactory results. Li et al. (2008) measured HPS contents using high-performance liquid chromatography (HPLC) along with an evaporative light scattering detector. For this process, HPS was separated and purified using a series of techniques to obtain glucose, xylose, rhamnose, galactose, and arabinose. Moreover, the phenol-sulfuric acid colorimetry method can determine only the total polysaccharide content but not the single component of polysaccharide. When using calorimetry, the conversion factor (f) value is needed to determine HPS, which increases the experimental error and affects the experimental efficiency. The HPLC method, in contrast, can determine the single component of polysaccharide and does not require the f value to measure HPLC content; the result, moreover, is more accurate. However, its sample pretreatment is cumbersome, and total polysaccharide content cannot be determined, so this method also has some limitations. Therefore, exploring a more efficient and accurate HPS determination method is required.

3 Study on the chemical structure of HPS

HPS, the primary active ingredient of *Hedysarum*, is being extensively studied in recent years. HPS are

heteropolysaccharides composed of monosaccharides and polysaccharide structures, with a polysaccharide content ranging from 23% to 34%. These polysaccharides consist of five monosaccharides, namely galactose, glucose, xylose, arabinose, and rhamnose (Table 2). To date, researchers have isolated and purified four HPS fractions from *Hedysarum* polysaccharide, namely *Hedysarum* polysaccharide 1 (HPS1), *Hedysarum* polysaccharide 2 (HPS2), *Hedysarum* polysaccharide 3 (HPS3), and *Hedysarum* polysaccharide 4 (HPS4) (Liu, 2007; Ma et al., 2008; Li et al., 2015a). The known structures of HPS include HPS1 (HPS1-A, HPS1-B, HPS1-C, HPS1-D), HPS3 (HPS3-A, HPS3-B, HPS3-C, HPS3-D), HPS4 (HPS4-1A, HPS4-1B, HPS4-2A), etc. However, the specific structural formula of HPS2 has not been reported in the literature.

HPS1 has been separated and purified to yield HPS1-A, HPS1-B, HPS1-C, and HPS1-D (Feng et al., 2014a; Yang et al., 2014a; Yang, 2014). HPS1-A is primarily composed of 1, 4- α -D-Glcp and 1, 4, 6- α -D-Glcp in the main chain. HPS1-B is an acidic polysaccharide with a relative molecular weight of 5.236×10⁵, and its main chain consists of 1, 4- α -D-Glcp and 1, 4, 6- α -D-Glcp. HPS1-C contains 1, 6- α -D-Glcp, 1, 4, 6- α -D-Glcp, 1,2- α -L-Rhap, and 1, 2, 4- α -L-Rhap in the main chain. HPS1-D is a neutral heteropolysaccharide with a relative molecular weight of 4.593 × 10⁴, andits main chain consists of 1, 4- α -D-Glcp and 1, 4, 6- α -D-Glcp. Figure 1 illustrates the structural formulas of HPS1-A, HPS1-B, HPS1-C, and HPS1-D.

HPS2 is a heteropolysaccharide with predominantly β -glycosidic bonds, but determining precise structure requires further research. HPS3 comprises four components, namely HPS3-A, HPS3-B, HPS3-C, HPS3-D. HPS3-A contains α -D-(1 \rightarrow 4) and glucopyranosyl group as the primary chain, while HPS3-B contains β -D-(1 \rightarrow 4) galactose and β -D-(1 \rightarrow 4) galacturonic acid in the main chain. HPS3-C is composed of β -D-(1 \rightarrow 4) galactosyl and β -D-(1 \rightarrow 4) galacturonic acid in the main chain, whereas HPS3-D consists of β -D-(1 \rightarrow 4) galactopyranosyl and β -D-(1 \rightarrow 4) galacturonic acid group as the main chain. The relative molecular masses of these components require further investigation. Figure 2 displays the structural formulas of HPS3-A, HPS3-B, HPS3-C, and HPS3-D.

Monosaccharide	Molecular formula	Molecular weight	Structural formula
Rhamnose	$C_6H_{12}O_5$	164.16	$HO \qquad OH \qquad$
Arabinose	$C_5H_{10}O_5$	150.13	HOOH
Glucose	$C_6H_{12}O_6$	180.16	HO OH OH
Xylose	$C_5H_{10}O_5$	150.13	OH OH
Galactose	$C_{6}H_{12}O_{6}$	180.16	

TABLE 2 Monosaccharide compounds of HPS.



(A). HPS1-A structural formula (B). HPS1-B structural formula (C). HPS1-C structural formula (D). HPS1-D structural formula. (Chinese Journal of New Drugs, 2018, 27(19): 2271–2280.).

HPS4 consists of three components: HPS4-1A, HPS4-1B, and HPS4-2A (Dang Z. L. et al., 2013; Dang Z et al., 2013; Feng et al., 2013). HPS4-1A is a neutral heteropolysaccharide with a relative molecular mass ranging from 7.386×10^4 to 6.68×10^5 , and its main

chain comprises 1,5 and 1, 3, 5 linked α -L-furanyl arabinose groups and 1, 6 and 1, 2, 6 linked α -D-galactopyranosyl groups. HPS4-1B has a relative molecular mass ranging from 20 to 5.023×10^4 , with 1, 4- α -D-Glcp and 1, 6- α -D-Galp formingthe main chain. HPS4-2A is



FIGURE 2

(A) HPS3-A structural formula. (B) HPS3-B structural formula. (C) HPS1-C structural formula. (D) HPS3-D structural formula (Chinese Journal of New Drugs, 2018, 27(19): 2271–2280.).



a thioylacetylaminoamino heteropolysaccharide with a relative molecular mass of 2.72105, and its main chain consists of 1, 3,4- β -D-2-acetyl aminogalactose, 1, 4, 6- α -D-glucose, 1, 4,6- β -D-galactose, and 1, 3, 6- β -D-galactose. Figure 3 illustrates the structural formulas of HPS4–1A, HPS4-1B, and HPS4-2A.

4 Pharmacological action of HPS

HPS has many pharmacological effects. In particular, nine of these effects have been thoroughly studied, including its anti-inflammatory, antitumor, antioxidation, anti-aging, and anti-fibrosis properties and its ability to lower blood sugar levels, regulate immune functions, improve Alzheimer's disease (AD) symptoms, and improve cerebral ischemiareperfusion injury (Figure 4).

4.1 Anti-inflammatory effect

Wang Jing et al. (Feng et al., 2014b) on studying the HPS effect on the expression of TIR-Domain-Containing Adapter-Inducing Interferon- β (TRIF) and tumor necrosis factor receptor-related factor 6 (TRAF6), a key molecule in the toll-like receptor 4 (Toll-4) signal transduction pathway in uveitis (EIU) model rats,



found that intraperitoneal injection of 400 mg/kg HPS in rats lowers the mRNA expression of TRAF6 and nuclear factor-kB (NF-kB). However, it has no obvious effect on the mRNA expression of TRIF, which indicates that HPS can alleviate the endotoxin lipopolysaccharide (LPS)-induced inflammatory reaction of the anterior segment in rats by inhibiting the expression of TRAF6 nucleic acid. This provides evidence that HPS has the potential to act as a drug that inhibits inflammatory response. Shuo Yang et al. (Qiang et al., 2018) found that after intraperitoneal injection of 400 mg/kg HPS in EIU model rats, phosphorylated GSK3-ß protein expression was upregulated in the iris and ciliary body, NF-KB p65 mRNA expression level was substantially suppressed, anti-inflammatory IL-10 levels in the aqueous humor were increased. In contrast, the levels of proinflammatory IL-6, TNF-a, and IL-1ß were inhibited, indicating that HPS could inhibit LPS-induced uveitis in rats. These findings suggest that HPS has a favorable anti-inflammatory effect. Zhang et al. (Shuo et al., 2019) discovered that local joint injections of 0.36 and 0.12 mg/joint could enhance the extension range of knee joints in OA rats, decrease synovial thickness, and elevate synovial glycosaminoglycan content. Furthermore, HPS reduced the expression of inflammatory markers such as IL-6, TNF-a, and IL-1 β in joint lavage fluid, indicating that HPS modulates inflammatory cells and factors to inhibit the inflammatory response. In addition, Wang Ximei et al. (Zhang et al., 2019) found that HPS (0.35 and 1.05 mg/joint) and HG-1 (0.15 and 0.45 mg/joint) can help increase the knee joint extension range in OA rats, inhibit abnormal articular surface synovial thickening, increase synovial glycosaminoglycan content, relieve free radical damage to cartilage, and improve the overall joint function in OA rats. These results suggest that HPS has the potential to be utilized for treating osteoarthritis (OA) and local inflammatory reactions in rats. In sum, HPS has satisfactory anti-inflammatory effects *in vivo*, closely related to the inhibition of IL-6, TNF- α , IL-1 β , and other inflammatory cytokines.

4.1.1 Inhibition of NF-κB signal pathway

Nuclear factor- κB (NF- κB) is a transcription factor that is activated by various signals through the degradation of IkBs. Once activated, NF-KB enters the nucleus to bind with DNA (Wang et al., 2018). NF-KB activation is strongly associated with the expression of inflammatory markers and the metabolic imbalance of the extracellular matrix (ECM) (Wu et al., 2018; Xie et al., 2018). Han Weiqiang et al. (Han et al., 2019) assessed HPS-related inflammatory response in obese (ob/ob) mice with diabetic peripheral neuropathy and discovered that administering HPS in dosages of 100 and 200 mg/kg reduces NF-KB protein and mRNA expression in the nerve tissue and then that of IL-1 β protein and mRNA; thus, reducing inflammation and protecting the nerves. HPS also reduces the expression of HMGB1, TLR4, NF-κB, IL-1β protein, and mRNA in the nerve tissue and reduces nerve tissue damage caused by inflammatory reaction; as a result, mice showed enhanced sciatic nerve conduction velocity and demyelination (He et al., 2019). Jin et al. (2017a) found that HPS can improve abnormal deposition of myocardial interstitial collagen in db/db mice and downregulate the expression of matrix metalloproteinase-9 (MMP-



9) and NF- κ B p65 and protein and mRNA in myocardial tissue. This outcome shows that HPS can aid in improving the abnormal myocardial collagen network structure, delaying the abnormal remodeling of myocardial interstitials, protecting cardiac function, and delaying myocardial interstitial fibrosis in diabetic cardiomyopathy (DCM). Inhibiting the activation of NF- κ B also has a significant role in preventing the occurrence and development of diabetic retinopathy (DR) (Zhao and Liu, 2016). To sum up, the ability of HPS to inhibit NF- κ B and its related proteins leads to the regulation of other protein expressions, ultimately resulting in the reduction of inflammation, delay in myocardial fibrosis, and prevention of diabetic retinopathy. HPS can reduce inflammation by suppressing the expression of NF- κ B and its protein in tissues and then regulating the expression of other proteins (Figure 5).

4.2 Antitumor effect

HPS can prevent the formation of tumors and help treat tumors by suppressing tumor growth, stimulating cell apoptosis, and supplementing the effects of chemotherapy drugs (Zhao Y. et al., 2015). Zeng et al. (2019) found that after treating oral cancer cells with 50 μ g/mL HPS for 24 h, apoptosis-related gene expression profiles, including Fas and Fas mRNA and related proteins of SCC25 were all upregulated, indicating that HPS may suppress the growth of SCC25 oral cancer cells and trigger their apoptosis via the Fas/Fasl pathway. In their study, Wang and Liu (2017) observed that treatment with 50, 100, or 200 mg/L of HPS-1 could regulate the oxidation-antioxidant capacity ratio of human lung adenocarcinoma (LUAD) A549 cells, resulting in the suppression of cell proliferation and induction of apoptosis. Additionally, it was found that HPS could attenuate the growth of LUAD A549 cells and induce apoptosis by modulating the cellular Bax/Bcl-2 ratio (Liu H. et al., 2016). Li et al. (2007a) evaluated the impact of HPS-3, 1 of the 3 components of HPS, on the proliferation and apoptosis of human gastric cancer MGC-803 cells in vitro by MTT assay, microfluorescence, and flow cytometry. HPS-3 at 200 g/L and 400 g/L for 72 h could induce cell apoptosis and inhibit the MGC-803 tumor cell growth and proliferation, thus, achieving an antitumor effect. The mechanism and regulation of HPS have been found to be closely associated with the modulation of Bax and Bcl-2 proteins' expression in the mitochondria. That is, HPS can inhibit the growth of oral cancer, lung adenocarcinoma, and human gastric adenocarcinoma, thus, possessing a wide range of effects. Li et al. (2007b) isolated and purified HPS to obtain 3 components of HPS (HPS-1, HPS-2, HPS-3), with HPS-1 and HPS-3 being regarded as the most important in preventing the growth of tumor cells. In addition, the antitumor effects of HPS depend on the molecular weight and monosaccharide composition of its components. To investigate the antitumor mechanism of HPS, a group of Chinese researchers treated LUAD cell A549 with varying concentrations of HPS and observed that HPS has the ability to induce apoptosis in these cells and reduce the expression of the Bcl-2 proto-oncogene protein. To further observe the cell-cycle inhibition and apoptosisinducing mechanism of HPS on HEP-G2 cells, the tumor cells were exposed to HPS at two distinct doses (200- and 400-µg/mL) for a total of 72 h. According to the findings, HPS exhibited the ability to inhibit the growth of human hepatoma HEP-G2 cells by inducing apoptosis, arresting cell cycle at the G2/M phase, and decreasing the expression of the proto-oncogene product Bcl-2 protein (Li and Zhang, 2009). Additionally, the administration of three HPS components, namely HPS-1, HPS-2, and HPS-3, to S180 tumorbearing mice showed promising potential in inhibiting tumor progression and enhancing the quality of life (Li and Zhang, 2009). Tian et al. (2015) showed that HPS might suppress bladder cancer in rats, and its mechanism may involve increasing

Pharmacological action	Function	Living mode	References
Inhibition of tumor cell, promote tumor cells apoptosis	Expression levels of both the mRNA of the genes Fas and Fas and their associated proteins were upregulated	SCC25	Zeng et al. (2019)
	Regulation of the oxidative/antioxidative capacity ratio in human A549 cells	A549 cells	Wang and Liu (2017)
	Regulation of the intracellular Bax/Bcl-2 ratio	A549 cells	Liu C. et al. (2016)
	Regulation of Bcl-2 and Bax protein expression in mitochondria	MGC-803 cells	Li et al. (2007a)
	Reduced expression of Bcl-2 protein	A549 cells	Liu C. et al. (2016)
	Blocking the progression of the G2/M phase of the cell cycle and reducing Bcl-2 protein	HEP-G2 cells	Li and Zhang (2009)
Enhances immune function and inhibits tumour angiogenesis	Increasing serum levels of IL-2. Reducing VEGF expression levels	Bladder cancer rats	Tian et al. (2015)
Inhibition of tumour cell metastasis	Inhibition of hepatocellular carcinoma cell metastasis via blood stream	Liver cancer mice	Wei et al. (2011)

TABLE 3 Anti-tumor effect mechanism of HPS.

the interleukin-2 (IL-2) level in the serum, enhancing the immune function, reducing the vascular endothelial growth factor (VEGF) expression level, and inhibiting tumor angiogenesis. Using a liver cancer mouse model, Wei et al. (2011) illustrated that HPS has the potential to prevent liver cancer cells from metastasizing via the blood flow. The studies mentioned above demonstrate that HPS exerts its anti-tumor effects through various mechanisms, such as activation of the Fas/Fasl pathway and upregulation of Bax expression leading to induction of apoptosis, enhancement of immunity via increased IL-2 levels, downregulation of Bcl-2 protein expression resulting in the promotion of apoptosis, reduction of VEGF expression leading to inhibition of tumor angiogenesis, arrest of the cell cycle in the G2/M phase, and inhibition of tumor cell growth. HPS exhibits potential antitumor properties against lung cancer, liver cancer, and bladder cancer, as summarized in Table 3.

4.3 Antioxidation

Several studies have shown that HPS and its active ingredients have unique anti-aging and antioxidation effects, and their active ingredients are mainly concentrated in polysaccharide compounds (Zhou et al., 2020). Yuan et al. (2019) adopted DPPH, superoxide 2,2'-diazobis (3-ethylbenzothiazoline-6-sulfonic anion. acid) [diammonium 2,2'-Azino-bis-(3-ethylbenzothiazoline-6-sulfonate), ABTS], and free radicals to measure the antioxidant activity of HPS. With the increase in HPS concentration, the scavenging ability of DPPH, superoxide anion, and ABTS increased, demonstrating a certain dose-effect relationship. Liu C. et al. (2016) found that HPS aqueous solution in dosages of 200, 100, and 50 µg/g showed anti-aging effects. After 42 days of intragastric administration in mice, the thymus and spleen indexes improved; this improvement helped slow down the atrophy of immune organs in aging animal models, thus, showing that through regulating T lymphocytes and increasing IL-4 levels, HPS efficiently enhanced the cellular and humoral immune capabilities in aged subacute mice. Zhao et al. (2014) adopted an anion exchange and gel permeation chromatography method to isolate a water-soluble polysaccharide (HPS3aS) measuring 1.22×10^4 Da in molecular weight from the Hedysarum root. The scavenging experiments with 1,1-diphenyl-2methylhydrazine, superoxide, and hydroxyl radical showed the good antioxidant activity of HPS3aS in vitro, implying that it is a potent antioxidant. HPS may also enhance Bcl-2 expression, suppress Bax expression, and effectively block the apoptosis of cells, thus, delaying the aging of brain cells (Shi et al., 2019). Kou et al. (2015) extracted and separated HPS components, namely, HPS-M, HPS-C, and HPS-H, using ultrasonic-assisted, microwave-assisted, and conventional hot water extraction methods, respectively. HPS-M showed higher antioxidant activity in vitro than HPS-C and HPS-H, and HPS-M showed a stronger ability to scavenge free oxygen radicals. The study by Yang Jie et al. investigated the effects of HPS on human brain microvascular endothelial cells under oxidative damage (Yang et al., 2016). HPS showed cellular protective effects of oxidized low-density lipoprotein, as it can potentially scavenge free radicals, inhibit apoptosis, and resist oxidative stress. To observe the effect of HPS on the scavenging rate of superoxide anion and hydroxyl radical in rats, some researchers injected 50, 100, 200, and 400 mg/kg HPS into the abdominal cavity of Wistar rats. According to Yang Jie et al., HPS was found to enhance the scavenging capacity of the superoxide anion and hydroxyl radical, as well as improve the activities of glutathione peroxidase and superoxide dismutase (SOD) (Lei et al., 2015). These studies suggest that HPS may increase the scavenging capacity of DPPH, superoxide anion, and ABTS in cells, improve immune organ atrophy, regulate T lymphocytes, and increase the level of IL-4. Additionally, HPS has been found to enhance the expression of Bcl-2, inhibit the expression of Bax, and suppress cell apoptosis. Furthermore, HPS has the potential to improve the scavenging capacity of hydroxyl radicals, and enhance the activity of glutathione peroxidase and superoxide dismutase (SOD), thus, providing resistance to oxidative stress. HPS exhibits strong antioxidant activity both in vivo and in vitro.

4.4 Effect of HPS on regulating blood sugar levels

Diabetes is a common endocrine and metabolic disease that causes considerable and serious damage to human health. According to the International Diabetes Federation, the number of diabetes cases worldwide is expected to increase from the current 425 million to an estimated 630 million by 2045 (Matoba et al., 2019). The HPS have a certain curative effect on diabetes, as they can help lower blood sugar levels and prevent and treat its various complications. HPS is under research for its ability to prevent and treat diseases of the kidney, myocardium, liver, retina, and nervous system caused by diabetes.

Mice with type 2 diabetes were given HPS in dosages of 50, 100, 200, 400, and 600 mg/kg for 28 days. According to Li Xiaodong et al. (Ye et al., 2020), HPS significantly improved blood lipid metabolism disorder by reducing levels of fasting blood glucose, glycosylated hemoglobin, total cholesterol, and triglycerides, while increasing high-density lipoprotein levels. Type 2 diabetes is characterized by the body's inability to effectively use insulin. To investigate the effects of HPS on type 2 diabetes, rats were administered doses of 50, 100, and 200 mg/kg of HPS-3 by Li et al. (2012). Blood glucose, glucose tolerance, and lipid profiles were measured after 5 weeks. HPS promoted glycogen production in the rats' livers, restored dysfunctional islet β cells, and reduced insulin resistance (IR). Oxidative stress–producing sex signal molecules can interfere with some insulin signal transduction pathways, leading to IR. Oxidative stress is closely related to inflammatory reactions.

Db/db mice were orally administered with HPS continuously for 8 weeks at doses of 200, 100, and 50 mg/kg, and the study showed the following outcomes: the peroxisome proliferator-activated receptor (PPAR) y protein, and mRNA expression were upregulated, while that of NF-kB mRNA and protein was downregulated. HPS can potentially alleviate oxidative stress and inflammatory reaction and inhibit the progress of myocardial fibrosis caused by hyperglycemia (Zhang et al., 2017a). Wang et al. (2013) illustrated that HPS had no impact on normal mice's blood sugar levels but may remarkably lower the blood sugar levels of the alloxan model mice and in the glucose tolerance test of normal mice and alloxan model mice, suggesting that the hypoglycemic mechanism of HPS is related to improving the body's sensitivity to insulin. Xu (2009), using alloxan to create a Kunming mouse model of type 1 diabetes mellitus (DM), showed that HPS at different molecular weight ranges had a satisfactory hypoglycemic effect, effectively increasing the liver glycogen content. HPS also improved the thymus and spleen indexes of these DM mice, which proved beneficial in reducing damage in other tissues caused by modeling and in lowering blood sugar levels. Zhao et al. (2009) extracted, separated, and purified HPS through stepwise alcohol precipitation. The systemic symptoms of DM mice treated with HPS-1, HPS-3, and HPS-4 showed improvement, the blood sugar level was significantly reduced, and the glucose tolerance level increased. These findings provide additional evidence of the significant hypoglycemic effects of HPS on both type 1 and type 2 diabetes, which offers new possibilities for utilizing plant polysaccharides in the treatment of diabetes. The studies mentioned previously demonstrate that HPS can reduce fasting blood glucose, glycosylated hemoglobin, total cholesterol, and triglyceride levels, increase high-density lipoprotein levels, and prevent hyperglycemia-induced myocardial fibrosis. Furthermore, HPS effectively enhances the expression of PPAR γ protein, increases liver glycogen content, and improves glucose tolerance levels.

4.4.1 Therapeutic effect of HPS on diabetes complications

Major vascular complications of diabetes include Diabetic nephropathy (DN), DCM, DR, nonalcoholic fatty liver disease (NAFLD), and diabetic neuropathy, with lipid-lowering and hypoglycemic therapy being the primary treatment methods used to prevent complications. HPS at different doses in DM rats can significantly improve blood glucose levels, decrease TC, TG, and LDL levels, and improve lipoprotein metabolism (Jin et al., 2004a). The available research on diabetic rat models has indicated that HPS might increase the levels of serum leptin, fat leptin, fasting blood glucose, and insulin sensitivity indices (Jin et al., 2011; Sun et al., 2014). HPS can also improve serum NO, NOS, and lipid peroxide levels in diabetic models (Jin et al., 2004b). Ding et al. (2012) showed that in type 2 diabetic rats, HPS-3 could reduce fasting blood glucose levels, improve spleen and thymus indexes, reduce the damage of high glucose levels to the immune organs of rats, and enhance the body's antioxidant defense ability.

4.4.1.1 Effect of HPS on diabetic DN

Diabetic neuropathy (DN) is a chronic complication of diabetes that not only contributes significantly to the disease but also leads to end-stage renal disease (ESRD). The pathogenesis of DN is mainly related to oxidative stress caused by hyperglycemia due to abnormal glucose and lipid metabolism (Sulaimon et al., 2020). Numerous studies by Chinese researchers have investigated the protective and therapeutic effects of HPS on diabetic neuropathy (DN). HPS can potentially slow the progression of renal interstitial fibrosis in a DN model by reducing the expression of connective tissue growth factor (CTGF) and transforming growth factor- β 1 (TGF- β 1) mRNA in the kidney (Qi et al., 2015a). Qi et al. (2015b) showed that HPS could slow down the progress of DN by inhibiting the expression of PKC protein and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) mRNA in glomerular mesangial cells or by inhibiting the overexpression of PCKa and its downstream VEGF. Jin Zhisheng (Jin et al., 2017b; Jin et al., 2017c) studied the effects of HPS at dosages of 200, 100, and 50 mg/kg on kidney tissues of db/db mice with early DN. Unlike the case in the model group, except for the low-dose HPS group, blood sugar, serum creatinine, urea nitrogen, and 24 h urine microalbumin levels in the treatment groups glomerular hypertrophy decreased, considerably reduced, mesangial area widened, and the capillary basement membrane thickened in different degrees. The protein and mRNA levels of CTGF and TGF-B1 in mouse kidney tissue were significantly reduced by HPS treatment. Additionally, HPS treatment resulted in a significant increase in both the mRNA and protein levels of MMP-2 in kidney tissue, while decreasing the levels of TIMP-1. HPS at 100 mg/kg had the most significant therapeutic effect. Thus, HPS has renal protective effects on early DN, which is worthy of further study. Thus, HPS can potentially prevent early DN and slow down neuropathy in diabetes by inhibiting the expression of CTGF, TGFβ1, PKC, TIMP-1, and VEGF proteins, increasing MMP-2 levels, and reducing serum creatinine, urea nitrogen, and 24-hour urine

microalbumin levels. These findings suggest that further research is needed to explore the therapeutic potential of HPS in the management of DN.

4.4.1.2 Effect of HPS on DCM

DCM, a cardiovascular complication of DM, has no specific treatment protocol. The primary mechanisms causing DCM, extracellular matrix remodeling, and myocardial fibrosis include oxidative stress and inflammatory responses caused by glucose and lipid metabolism disorder. HPS can help delay DCM onset and other cardiac protection (Wang et al., 2017; Dong et al., 2018). Recent studies have indicated that the TGF-\u03b31/Smads signaling pathway is involved in the ability of HPS to decrease myocardial fibrosis in an animal model of DCM (Jin et al., 2017d). He et al. (2017) showed that HPS upregulated PPAR by reducing blood glucose and lipid-y levels. The progression of DCM can be delayed by increasing GLUT-4 expression. HPS has been shown to mitigate the apoptosis of human umbilical vein endothelial cells (HUVEC) caused by high glucose levels, according to Liu et al. (2012). Dong (2018) found that in the DCM model, HPS treatment increased B-cell lymphoma/ leukemia-2 (Bcl-2) expression in db/db mouse myocardium tissue while decreasing caspase-3 and Bax expression. HPS has been shown to increase TGF-B1/Smads, GLUT-4, and Bcl-2 expression while decreasing the expression of caspase-3 and Bax, thereby alleviating diabetes cardiomyopathy.

4.4.1.3 Effect of HPS on DR

DR is another important complication of diabetes, which can lead to blindness in patients with diabetes. HPS can potentially inhibit neovascularization and proliferation in DR by elevatingTSP-1 expression level and reducing the platelet-derived growth factor (PDGF)-B expression level in the retina of diabetic rats to protect the retina (Zhang et al., 2017b). HPS can also inhibit neovascularization and proliferation through the VFGF in the retina to prevent DR (Ru et al., 2015; Zhang et al., 2016; Shan et al., 2017). HPS reduces neovascularization and proliferation by promoting the expression of TSP-1 and PDGF-B in the diabetic retina and explains its mechanism of action (Zhang, 2018). Li (2019) administered $30\,\mu\text{g/g}$ of streptozotocin intraperitoneally twice to normal rats to induce a diabetic model. After 12 weeks of treatment, the retina thickness and cell organization of the HPS group improved. The levels of pro-apoptotic factors (Bcl-2x), nuclear factor E2-related factor (Nrf2), and SOD levels were increased in the retinal tissue of the HPS group. In contrast, the levels of apoptotic factors Bax and inducible nitric oxide synthase (iNOS) were decreased. The Bcl-2/ Bax positive cell ratio was significantly higher in the HPS group than in the diabetic model group. HPS can activate the Nrf2 pathway, promote the production of the antioxidant enzyme SOD, reduce the iNOS content, reduce the apoptosis of retinal tissue, and protect the retinal tissue. HPS has been shown to increase the expression levels of TSP-1, Bcl-2x, Nrf2, and SOD, while decreasing the expression levels of Bax, iNOS, PDGF-B, and VEGF, thus, delaying the onset of DR.

4.4.1.4 Effect of HPS on diabetes NAFLD

Nonalcoholic fatty liver disease (NAFLD) refers to a range of liver conditions caused by metabolic stress and strongly associated with insulin resistance, including nonalcoholic simple fatty liver, nonalcoholic fatty liver hepatitis, liver cirrhosis, and hepatocellular carcinoma (Fan and Farrell, 2009). The incidence of NAFLD is as high as 70%-90% in patients who are obese and have type 2 diabetes (Kirpich et al., 2015; Tokita et al., 2017). Shang Hongxia et al. (Shang et al., 2014) proved that HPS could reduce the serum levels of lowdensity lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST), triacylglycerol, and alanine aminotransferase (ALT) in NAFLD rats but increases the levels of high-density lipoprotein cholesterol (HDL-C) and the expression of SOD-1 gene in the liver tissue, as well as regulates the lipid metabolism disorder in NAFLD rats. Sun et al. (2014) evaluated Sprague-Dawley rats with NAFLD caused by a high-fat diet. HPS can upregulate the PPAR by phosphorylating AMP-activated protein kinase (AMPK)-a and PPAR-a. However, sterol regulatory element binding protein-1c (SREBP-1c) was downregulated to reduce liver fat production and increase lipid decomposition, thus, improving lipid metabolism disorder. HPS has been shown to have potential in treating NAFLD by lowering LDL-C, AST, ALT, and SREBP-1c levels while increasing HDL-C, SOD-1, phosphorylated AMP, and AMPK-a levels. Additionally, HPS may increase PPAR-a expression, which can further improve NAFLD.

4.4.1.5 Effect of HPS on diabetic neuropathy

The lifetime incidence of diabetic neuropathy is about 45% in T2D and 54%-59% in T1D (Feldman et al., 2019). Hyperglycemia is the most important factor causing peripheral diabetic neuropathy, but its pathogenesis remains unclear (Alam, 2020). At present, most theories tend to explain diabetic neuropathy through chronic glucose metabolism disorder and neuromicrovascular ischemia. In addition, the changes in neurotrophic factors, inflammation, and oxidative stress caused by high glucose levels, Schwann cell apoptosis, and immune response also perform an integral function in diabetic peripheral neuropathy (Hinder et al., 2012; Vincent et al., 2013). Ji et al. (2019) illustrated that HPS could lower the severity of nerve tissue fibrosis in peripheral diabetic neuropathy in ob/ob mice, with its mechanism being the elevation in the activity of antioxidant enzymes in vivo by upregulating Nrf2 and downregulating the expression of Keap1 protein and gene. Han et al. (2019) showed that HPS could increase sciatic nerve conduction velocity in ob/ob mice with diabetic peripheral neuropathy, decrease the expression level of NF- κ B and IL-1 β protein and gene, and reduce the inflammatory reaction of sciatic nerve tissue. In summary, HPS has been shown to improve the symptoms of diabetic neuropathy by upregulating Nrf2 and downregulating Keap1 protein, as well as inhibiting NF-κB and IL-1β expression.

4.5 Immunomodulatory effect

Yan et al. (2017) administered 100 mg/kg/d HPS aqueous solution in immunosuppressive model rats for 7 days and found an increase in the peripheral blood hemogram count, IL-2, IL-4, interferon- γ (IFN- γ), immunoglobulin-G (IgG), IgM, IgA, and immune cytokine levels, and the thymus and spleen indexes. Combining complex enzymes with ultrasonic technology, Yang et al. (2019) extracted and isolated HPS-MC, HPS-MC (50%), and HPS-MC (80%). Under cyclophosphamide-induced immunosuppressive conditions, HPS-MCs, particularly HPS-MC

Cytokine	Influence	Model	References	
IL-2	Upregulation	In vivo	Yan et al. (2017)	
IL-4	Upregulation	In vivo	Yan et al. (2017)	
IFN-γ	Upregulation	In vivo	Yan et al. (2017)	
TNF-α	Downregulation	In vivo	Yan et al. (2017)	
TGF-β1	Downregulation	In vivo	Jin et al. (2017d)	
VEGF	Downregulation	In vivo	Shan et al. (2017)	
CRP	Downregulation	In vivo	Shan et al. (2017)	
PEDF	Upregulation	In vivo	Shan et al. (2017)	
TSP-1	Upregulation	In vivo	Zhang et al. (2017b)	
PDGF-B	Downregulation	In vivo	Zhang et al. (2017b)	

TABLE 4 Effects of HPS on cytokines.

(80%), exhibited potent immunoregulatory effects. HPS can help improve nonspecific immune functions, specific humoral immune functions, and cellular immune functions in cyclophosphamide-induced immunocompromised mice (Shao et al., 2017a) and comprehensively and significantly regulate all immune indexes. Studies have shown that HPS can enhance immune function by increasing peripheral blood count, IL-2, IL-4, and interferon- γ levels, as well as the levels of IgG, IgM, IgA, and immune cytokines, and the indexes of thymus and spleen.

4.5.1 Regulation of various cytokines

In the late 18th century, Roberts (Fennen et al., 2016), in the process of inducing rat fibroblasts to proliferate, discovered and then isolated TGF- β , a polypeptide protein. TGF- β , extensively found in tissues and transformed cells, helps regulate the growth, differentiation, and immune functions of cells (Guo and Sun, 2020). Jin et al. (2017d) found that HPS injected in DCM mice helped improve left ventricular myocardial remodeling and myocardial collagen deposition, inhibit the release of TGF-\$1 and Smad2, Smad3 protein and mRNA expression in myocardial tissue, and regulate abnormal structure and function of the heart, finally delaying the progress of myocardial fibrosis. Numerous cytokines, such as PDGF and VEGF, are important factors affecting angiogenesis, inducing the myofibroblast-like phenotype of cells and helping prevent and treat vascular diseases (Siedlecki et al., 2018; Shamsdin et al., 2019). Shan et al. (2017) illustrated that intragastric administration of HPS in dosages of 50, 100, and 150 mg/kg reduces serum C-reactive protein (CRP) levels, alleviates inflammatory reactions, reduces VEGF levels, increases pigment epithelial cellderived factor (PEDF) levels in the retinal tissue, and inhibits retinal neovascularization, protecting the retina. In addition, Zhang et al. (2017b) discovered that HPS in different doses caused the enhanced expression of thrombospondin-1(TSP-l) and the attenuated expression of PDGF-B to inhibit angiogenesis and proliferation in DR rats. Therefore, HPS can regulate various cytokines, such as inhibiting TGF-B1, Smad2, Smad3 protein, CRP, and VEGF levels, and increasing the expression of PDGF and TSP-1. This regulation is beneficial in the prevention and treatment of diabetes complications, as shown in Table 4.

4.5.2 Regulation of immune cells

Early studies have shown that HPS administered in mice lymphocyte transformation promotes and has an immunomodulatory effect (Mao and Wang, 1989). Sun et al. (1994) found that HPS has both immunomodulatory and antiaging effects on mouse cells. Researchers administered HPS-1, HPS-2, and HPS-3 to S180 tumor-bearing mice for 14 days to observe their regulating effect on the immune system. Blood, spleen, thymus, and tumor were excised for further study. HPS increased the thymus and spleen indexes, improved lymphocyte transformation function, and increased NK and LAK cell activity (Shao et al., 2017a). Li et al. (2015b) conducted an assessment of the impact of HPS on T cells and reported differential protein dot expression of HSP-3 on mouse spleen cells. HPS-3 was found to enhance the proliferation ability of T lymphocytes and IL-2 secretion. It was also observed that HPS may have influenced the protein expression in mouse spleen cells. Wan (2012) illustrated that HPS improved spleen deficiency in rats, increasing CD3⁺ T and CD4⁺ T cell counts. Subsequent studies have also shown that HPS can regulate immunity, enhance immunity, and increase the T lymphocyte subset levels (Shao et al., 2017b). Several research studies have reported that there is a dose-response pattern and variability in the anti-complement activity of individual HPS components (Yang et al., 2014b). Additionally, these studies further support that HPS has immunoregulatory effects and can promote lymphocyte transformation and proliferation, increase the activity of NK and LAK cells, enhance IL-2 secretion, and increase the count of CD3⁺T and CD4⁺T cells as well as the index of thymus and spleen. Consequently, HPS has a promising application potential for treating immunosuppressive disorders and warrants further development and application.

4.6 Effect of HPS on Alzheimer's syndrome

AD is a type of senile dementia, with its primary clinical manifestation being the gradual decline of cognitive and life functions. Commonly used therapeutic drugs are N-methyl-D-aspartate receptor (NMDAR) antagonists and acetylcholinesterase (AChE) inhibitors, but their effectiveness is not satisfactory. In China, because of the known curative effects of TCM, these have been applied to treat AD for hundreds of years. Jewel (2015) confirmed that the protective effect of HPS on the AD cell model is related to its ability to regulate the expression of choline kinase A, Rag regulatory protein complex LAM-TOR1, transcription factor protein AP-2- δ , and ferritin. In addition, to confirm the same mechanism, Chloe et al. (2018) added HPS to SH-SY5Y cells with a final concentration of 20 µg/mL for pre-incubation for 4 h and then added A β 1–42 with a final concentration of 5 μ M to continue incubation for 48 h and then extracted total cell proteins. HPS and Se-HPS3 have been shown to have neuroprotective effects against oxidative stress and apoptosis in SH-SY5Y human neuroblastoma cells induced by AB25-35 and can potentially prevent or treat neurodegenerative diseases (Wei et al., 2015). Ling (2018) established an Alzheimer's disease cell model in PC12 cells using $A\beta$ as a stimulus. Their research found that HPS protected PC12 cells by upregulating the expression of PRKCB, which inhibited AP25–35-induced apoptosis of PC12 cells by regulating the mitochondrial apoptosis pathway through ERK1/ 2 signaling. The aforementioned research results provide data support for the research and development of new HPS drugs and their derivatives.

The aforementioned research findings indicate that HPS modulates various proteins, such as choline kinase A, LAM-TOR1, AP-2- δ , and ferritin, while also upregulating PRKCB expression. Moreover, the ERK1/2 signal-mediated PRKCB has a therapeutic effect on Alzheimer's disease.

4.7 Anti-aging

DNA methylation, changes in telomere and telomerase, abnormal free radicals, and abnormal regulation of nervous, endocrine, and immune systems are factors responsible for accelerating the aging process (Xie and Meng, 2018). HPS has anti-free radical damage and anti-aging impacts. Huang et al. (1992) proved that HPS could prolong the lifespan of Drosophila melanogaster, improve the nonspecific resistance of aged mice to harmful stimuli, reduce lipid peroxide levels in plasma, and reduce lipofuscin formation. It is further proved that HPS can increase the SOD content of red blood cells and serum cortisol and testosterone levels in aged rats. Shi et al. (2019) found that the content of antioxidant GSH-Px and SOD in HPS increased, and the content of pro-oxidant MDA and MAO decreased, confirming that HPS had both antioxidant and anti-aging impacts. HPS has the potential to slow down the aging of brain cells by increasing the expression of Bcl-2, reducing Bax expression, and preventing cell apoptosis. This anti-aging effect of HPS is further supported by the aforementioned studies. Moreover, the studies suggest that HPS exhibits anti-aging properties by decreasing lipid peroxide levels, reducing lipofuscin, MDA, and MAO content, and increasing serum cortisol and testosterone, as well as GSH-Px and SOD levels.

4.8 Anti-fibrosis

HPS can significantly improve liver fibrosis caused by carbon tetrachloride in mice and also considerably improve bone loss caused by liver fibrosis (Chen et al., 2016). Wang et al. (2022) studied the anti-pulmonary fibrosis effect of different extracts of Hedysarum. A rat model of pulmonary fibrosis was created by administering bleomycin through a laryngoscope, after which the rats were given different drugs for intervention. HPS, flavonoids, and saponins were found to inhibit the proliferation and deposition of collagen fibers and improve the pulmonary interstitial fibrosis and alveolar inflammatory reaction in the rats. Han et al. (2013) proved that HPS could reduce levels of serum ALT, AST, laminin (LN), type III procollagen (PC III), hyaluronic acid (HA), type IV collagen (IV-C), and hydroxyproline (Hyp), as well as the number of collagen fibers in liver fiber model rats. HPS has demonstrated its potential as an anti-fibrotic agent in rats by inhibiting the proliferation and deposition of collagen fibers, reducing their number, and improving pulmonary interstitial fibrosis and alveolar inflammatory reaction. Moreover, it was found to decrease the levels of serum ALT, AST, LN, PC III, HA, IV-C, and Hyp.

4.9 Improvement in cerebral ischemiareperfusion injury

Shao et al. (2018) found that anticipatory administration of HPS in rats enhances the antioxidant function of the brain tissue and the self-repair ability of damaged brain tissue and alleviates abnormal changes in the blood flow, thus, reducing the brain tissue and nerve function damage caused by acute focal cerebral ischemia and achieving the protective effect. Geng Geng et al. (2020) confirmed the protective function of HPS on the hippocampus of rats with cerebral ischemia-reperfusion injury, and IL-6, TNF-a, and IL-10 levels in the brain tissue of rats significantly decreased after administration of 200 mg/kg of HPS for 10 days. Anti-inflammatory factors are secreted under induction by HPS, which aids in the regulation of both pro-and anti-inflammatory factors, thus, reducing the inflammatory reaction of cerebral ischemiareperfusion injury and exerting its protective effect. HPS has been shown to improve the antioxidant function and selfrepairing ability of brain tissue, decrease abnormal changes in blood flow, lower levels of pro-inflammatory cytokines such as IL-6 and TNF-a, increase the level of the anti-inflammatory cytokine IL-10, and regulate the balance between proinflammatory and anti-inflammatory factors; thus, providing a potential therapeutic effect for cerebral ischemia-reperfusion injury.

5 Summary and research prospect

HPS is the primary active ingredient of Hedysarum, a traditional Chinese medicine possessing multi-component and multi-target characteristics. Its pharmacological activities are wide-ranging, playing an irreplaceable role in the treatment of modern diseases. Nine main pharmacological effects of HPS have been detailed in this study, namely, inhibition of inflammatory reaction. antioxidation, immunomodulation, anti-aging, antitumor, lowering blood sugar levels, preventing and treating AD, lowering blood lipid levels, anti-fibrosis, improving cerebral ischemia-reperfusion injury. HPS promotes the repair and regulation of the immune system. Among the several anti-aging effects of HPS, its antioxidation mechanism is the most important one; HPS is also effective in preventing and treating cancer. HPS has been shown to exhibit antitumor properties by suppressing the growth of tumor cells and promoting tumor cell apoptosis. In addition, HPS has potential therapeutic applications for managing diabetes and associated complications. HPS has been found to significantly decrease levels of blood glucose, TC, TG, LDL, NO, NOS, and lipid peroxide, while also improving lipoprotein metabolism. Moreover, HPS has been shown to increase serum leptin and fat leptin levels, fasting blood glucose, and insulin sensitivity index. HPS has also been found to enhance the spleen and thymus index, thereby providing a potential treatment option for diabetes complications. HPS, as a natural medicine, has almost no toxic or side effects and is suitable for long-term use by patients with chronic diseases. Therefore, HPS has great potential in treating diseases.

However, there are some shortcomings in the current research situation. (1) Whether it is *Hedysarum* monomer or its compound, clinical application research is still lacking. (2) Except on HPS,

studies on the pharmacological effects of isoflavones from Hedysarum stilbene are few. (3) At present, research on the effect of HPS has been conducted on only cells and animals, and its specific pharmacodynamic material basis remains unclear. (4) Only a few reports exist on the structural modification of HPS. Therefore, future studies should expand the research scope and depth of HPS, explore whether different HPS modifiers can enhance its immunomodulatory function, and further determine the pharmacological effects of Hedysarum active ingredients from the classic prescription. The biological activity of more structural modifiers of HPS and the efficacy comparison of different administration methods need to be explored. The mechanisms of its effects of reducing blood lipid levels, resisting fibrosis, and preventing radiation need to be clarified. Moreover, although HPS exerts various pharmacological effects, the precise control of its dosage needs further study.

HPS is a natural compound. Currently, the main challenge in HPS research is to identify its specific components and determine its precise targets. It is important to accurately detect the nine pharmacological targets of HPS and demonstrate the remarkable effect of multi-target integration in traditional Chinese medicine. This can help fill the gaps in the research of pharmacological effects from the perspective of HPS and provide significant theoretical support for the clinical management of illnesses. It can also provide direction for further research on new ways of treating diseases with traditional Chinese medicine.

Author contributions

YDL and XKZ edited this paper and proposed views. XG, CZR, and LYL was in charge of writing the paper and information gathering. The paper was translated and corrected by KL and

References

Alam, U. (2020). Diabetic neuropathy collection: Introduction to diabetic neuropathy. *Diabetes Ther.* 11, 755–760. doi:10.1007/s13300-020-00773-6

Bai, H. Y., Zhang, K. X., Bao, F., et al. (2020). Comparative research progress of Astragalus and Hedys-ari radix [J]. Northwest Pharm. J. 35 (3), 460-466.

Chen, T., Adilbekov, J., Zhao, L., Guo, C., Wong, M. N., Huang, Y., et al. (2012). Analysis of monosaccharide composition and determination of polysaccharide content of four fractions of *Hedysarum* polysaccharide 3[J]. *Chin. J. Pharmacol.* 47 (7), 551–559. doi:10.1161/CIRCRESAHA.111.255927

Chen, X., Li, J., Liu, X., Chen, Y., Hong, Y., Feng, S., et al. (2016). Preventive and therapeutic effects of HPS on CCl4-induced liver fibrosis and bone loss in mice[J]. *Chin. Herb. Med.* 47 (2), 290–296.

China Pharmacopoeia (2020). China Pharmacopoeia [S], 159.

Chloe, W., Wei, D., Jewel, L., Zhou, Q., Ren, J., Zhang, J., et al. (2018). Study on the difference of protectiveeffect of HPS on cell model of Alzheimer's disease in protein[J]. *Pharmacol. Clin. Traditional Chin. Med.* 34 (3), 62–68.

Dang, Z., Feng, D., Liu, X., Yang, T., Guo, L., Liang, J., et al. (2013). Structure and antioxidant activity study of sulfated acetamido-polysaccharide from Radix Hedysari. *Fitoterapia* 89 (1), 20–32. doi:10.1016/j.fitote.2013.05.011

Dang, Z. L., Liu, S. H., Zhao, A., Liang, J., and Liang, J. (2013). Chemical structure characterization and preliminary molecular conformation analysis of *Hedysarum* polysaccharide HPS4-1A[J]. *Chin. Herb. Med.* 44 (2), 141–146.

Ding, Y., Li, X., Li, J., and Feng, S. (2012). Effects of HPS-3 on lipid peroxidation, thymus index and spleen index in experimental type 2 diabetic rats[J]. J. Lanzhou Univ. Med. Ed. 38 (4), 19–22.

Dong, W. (2018). Effect of HPS on protein and gene expression of Bax, Bcl-2 and Caspase-3 in diabetic cardiomyopathy db/db mice[D]. Lanzhou: Gansu University of Traditional Chinese Medicine.

HLZ. MJZ, HGJ, XFL, XDZ, and QLC delivered their thoughts on the article's diagrams and charts. The final version of the paper was reviewed and approved by all authors.

Funding

This is work was supported by the 2021 Jiaoyu Jiebang Guashuai Project (No. 2021 jyjbgs-03), 2022 Gansu Province Longyuan Youth Innovation and Entrepreneurship Talent Project, 2022 Gansu Province outstanding graduate student "Chuangxin Zhi xing" project (NO. 2022CXZX-736), 2022 Gansu Province natural sciences fund (22JR11RA128) and National Natural Science Foundation of China (NO. 82260869), National Administration of Traditional Chinese Medicine Youth Qihuang Scholars Support Project.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Dong, W., Jin, Z., He, L., et al. (2018). Effect of HPS on cardiomyocyte apoptosis in db/db mice with diabetic cardiomyopathy[J]. *China J. Clin. Pharmacol.* 34 (11), 1330–1333.

Fan, J. G., and Farrell, G. C. (2009). Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatology 50 (1), 204–210. doi:10.1016/j.jhep.2008.10.010

Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., et al. (2019). Diabetic neuropathy. *Nat. Rev. Dis. Prim.* 5 (1), 41. doi:10. 1038/s41572-019-0092-1

Feng, H. M., Li, C. Y., He, J. G., Qiang, Z. Z., and Jia, M. T. (2021). Research progress on chemical constituents and pharmacolo-gical effects of *Hedysari* radix and predictive analysis on quality markers [J]. *China Herb. Med.* 52 (9), 2831–2842.

Feng, S., Zhao, L., Feng, D., Dang, Z., Liu, X., Cui, F., et al. (2013). Preparation and application of Hedysarum polysaccharide 4 and its active ingredient: Chinese patent. CN103073650A [P].

Feng, S., Zhao, L., and Yang, T. (2014a). A Hedysarum polysaccharide 1, its four isolates and its preparation method and application: China. CN103709266A [P].

Feng, S., Zhao, L., and Yang, T. (2014b). An HPS1, its four isolates, their preparation methods and applications: China. CN103709266A[P].

Fennen, M., Pap, T., and Dankbar, B. (2016). Smad-dependent mechanisms of inflammatory bone destruction. *Arthritis Res. Ther.* 18 (1), 279. doi:10.1186/s13075-016-1187-7

Geng, G., Shao, J., Xie, X., and Yang, Z. (2020). Protective effect of HPS on hippocampus of rats with cerebral ischemia-reperfusion injury[J]. *China J. Clin. Pharmacol.* 36 (9), 1107–1109.

Guo, S., and Sun, L. (2020). Research progress of bone growth factor in bone repair[J]. labeled immunoassays Clin. Med. 27 (1), 173–177.

Han, T., Wang, Y., Wu, G., Shi, Y., and Guo, Q. (2013). Pharmacological effect of HPS on liver fibrosis[J]. *China J. Gerontology* 33 (12), 2810–2812.

Han, W., Jin, Z., He, L., Zhang, H., Ji, F., Zhang, L., et al. (2019). Effect of HPS on inflammatory response of diabetic peripheral neuropathy ob/ob mice[J]. *China J. Clin. Pharmacol.* 35 (6), 539–542.

He, C., Jin, Z., Zhang, H., Wang, D., Nang, X., Shi, G., et al. (2017). Effect of HPS on improving myocardial injury in db/db mice with diabetic cardiomyopathy[J]. *China J. Clin.* 33 (5), 418–422.

He, L., Jin, Z., Zhang, L., et al. (2019). Effect of HPS on signaling pathway of highmobility group protein 1-Toll-like receptor 4 in diabetic peripheral neuropathy ob/ ob mice [J]. *China J. Clin. Pharmacol.* 35 (7), 657–660.

Hinder, L. M., Vincent, A. M., Burant, C. F., Pennathur, S., and Feldman, E. L. (2012). Bioenergetics in diabetic neuropathy: What we need to know. *J. Peripher Nerv. Syst.* 17, 10–14. doi:10.1111/j.1529-8027.2012.00389.x

Huang, Z., Cui, Z., Ren, Y., Zhang, J., Gan, M., Qi, W., et al. (1992). Experimental study on anti-aging effect of HPS[J]. *Chin. Herb. Med.* 23 (9), 469–473.

Hui, H., Feng, S., Zhao, L., Shi, Y., and Liu, X. (2010). Purification and preliminary structure identification of *Hedysarum* polysaccharides[J]. *Shi-Zhen Guomao* 21 (9), 2302–2303.

Jewel, L. (2015). Study on the effect of HPS on protein expression profile of Alzheimer's cell model[D]. Lanzhou: Lanzhou University, 14–30.

Ji, F., Jin, Z., He, L., Han, W., Zhang, H., Zhang, L., et al. (2019). The improvement effect of HPS on nerve tissue fibrosis in diabetic peripheral neuropathy mice and its mechanism[J]. *China J. Clin. Pharmacol.* 35 (7), 661–663.

Jia, M. T., Li, C. Y., Sun, T. X., Wang, L., Qiang, Z. Z., Li, B., et al. (2020). New progress in pharmacological study of *Hedysari* radix [J]. *Pharmacol. Clin. China Mater Med.* 36 (6), 235–239.

Jin, Z., Ru, Y., Chu, H., Chu, H., Wu, L., Ma, J., et al. (2004a). Effects of HPS on serum NO, NOS and lipid peroxide in diabetic rats with different course[J]. *Shanghai J. TraditionalChinese Med.* 38 (6), 44–46.

Jin, Z., Ru, Y., Li, Y., Chu, H., Wu, L., and Ma, J., et al. (2004b). Effect of HPS on blood lipid of diabetic rats with different course of disease[J]. J. Integr. Chin. West. Med. Cardiovasc. Cerebrovasc. Dis. 2 (5), 278–280.

Jin, Z., Sun, D., Ru, Y., Li, J., Gao, Y., Chu, H., et al. (2011). Effect of HPS on SOD and MDA in brain tissue of experimental diabetic rats with insulin resistance[J]. *J. Gansu Coll. Traditional Chin. Med.* 28 (1), 5–9.

Jin, Z., Wang, D., He, C., Zhang, H., Zhang, P., He, L., et al. (2017a). Effect of HPS on the expression of NF-κBp65 and MMP-9 in diabetic cardiomyopathy of db/db mice[J]. *J. Jinan Univ. Nat. Sci. Med. Ed.* 38 (5), 380–386.

Jin, Z., Wang, D., Zhang, H., He, C., Nan, X., Wang, Q., et al. (2017b). Experimental study on the effect of HPS on TGF- β 1/Smads signal pathway of diabetic cardiomyopathy in db/db mice[J]. *J. Beijing Univ. Traditional Chin. Med.* 40 (1), 20–26.

Jin, Z., Wei, Y., Lin, H., Shao, J., and Zhang, H. (2017c). Effect of HPS on MMP-2 and TIMP-1mRNA and protein expression in early diabetic nephropathy db/db mice[J]. *Pharmacol. Clin. Traditional Chin. Med.* 33 (4), 66–70.

Jin, Z., Wei, Y., Lin, H., and Zhang, H. (2017d). Effect of HPS on renal interstitial fibrosis in early diabetic nephropathy db/db mice[J]. *J. Beijing Univ. Traditional Chin. Med.* 40 (8), 677–683.

Kirpich, I. A., Marsano, L. S., and McClain, C. J. (2015). Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. *Clin. Biochem.* 48 (13–14), 923–930. doi:10.1016/j. clinbiochem.2015.06.023

Kou, N., Li, L., Li, Q., and Chen, W. (2015). Effects of different extraction methods on antioxidant activity of HPS in vitro[J]. Food Industry Sci. Technol. 36 (15), 100–103.

Lei, F., Yue, S., Sun, L., Zhang, C., and Sang, Y. (2015). Regulation of HPS on free radical scavenging and antioxidant capacity in aging rats[J]. *Shandong Med.* 11, 11–13.

Li, B., Feng, S., Liu, X., Ma, D., Li, X., Hu, F., et al. (2008). Determination of HPS in radix *Hedysarum* by HPLC[J]. *Chin. Pat. Med.* 30 (5), 716–718.

Li, L., Xu, J., Kou, N., and Chen, W. (2015a). Differential protein spotsa nalysis of spleen lymphocytes from mice proliferation promoted with *Hedysarum* polysaccharides [J]. *Liaoning J. Tradit. Chin. Med.* 42 (12), 2449–2453.

Li, L., Xu, J., Kou, N., and Chen, W. (2015b). Protein dot analysis of the difference of HPS3 promoting the proliferation of mouse spleen lymphocytes[J]. *Liaoning J. Traditional Chin. Med.* 42 (12), 2449–2453.

Li, S., and Zhang, Y. (2009). Mechanism of hedysari polysaccharide in the apoptosis of human hepatocellular carcinoma HEP-G2 cells. *Chin. Herb. Med.* 32 (8), 1249–1251.

Li, S., Zhang, Y., Zhao, J., Wang, X., and Liu, Z. (2007a). Study on the antitumor activity and structure-activity relationship of HPS *in vitro*[J]. *Pharmacol. Clin. Traditional Chin. Med.* 23 (6), 35–37.

Li, S., Zhang, Y., Zhao, J., Wang, X., Liu, Z., et al. (2007b). Study on apoptosis of human gastric cancer MGC-803 cells induced by HPS-3 *in vitro*[J]. *Pharmacol. Clin. Traditional Chin. Med.* 25 (3), 49–54. doi:10.1080/07391102.2007.10507154

Li, X., Feng, D., Zhao, L., and Feng, S. (2012). Effect of HPS HPS-3 on glucose and lipid metabolism and pathological changes of pancreatic tissue in type 2 diabetic rats[J]. *Pharmacol. Clin. Traditional Chin. Med.* 28 (1), 83–86.

Li, Y. (2019). Effect of HPS on Nrf2 pathway in retina of diabetic rats[D]. Tangshan: North China University of Science and Technology.

Ling, J. (2018). Protective effect of HPS on PC12 cell apoptosis induced by $A\beta 25$ -35 through PRKCB/ERK pathway[D]. Guangzhou: Southern Medical University, 42–70.

Liu, B., Guo, Y., Diao, P., and Chen, F. (2007). Comparative study of microwaveultrasonic extraction and conventional extraction of HPS[J]. *Anhui Agric. Sci.* 35 (30), 9703–9722.

Liu, C., Kou, N., Zhang, G., Li, L., Pang, D., and Chen, W. (2016). Study on the antiimmune aging effect of HPS on aging mice induced by D-galactose[J]. *Chin. Med. Res.* 29 (6), 63–68.

Liu, H., Yan, L., Wang, X., Qin, G., and Chen, T. (2016). Glucose-reduced graphene oxide with excellent biocompatibility and photothermal efficiency as well as drug loading. *Med. J. Natl. Defending Forces Northwest China* 37 (4), 211–213. doi:10.1186/ s11671-016-1423-8

Liu, J., Deng, W., Fan, L., Tian, L., Jin, L., Jin, Z., et al. (2012). The role of Radix *Hedysari* polysaccharide on the human umbilical vein endothelial cells (HU-VECs) induced by high glucose[J]. *Eur. J. Intern Med.* 23 (3), 287–292. doi:10.1016/j.ejim.2011. 10.006

Liu, Z. (2007). Experimental study on extraction of Hedysarum polysaccharides and its antitumor effect[D]. Lanzhou: Lanzhou university.

Ma, D., Feng, S. L., Zhao, L. G., Liu, X. H., Li, B., Li, X. D., et al. (2008). Purification of *Hedysarum* polysaccharides and determination of its constitution[J]. *Chin. J. Mod. Appl. Pharm.* 3, 177–179.

Ma, D. (2008). Extraction, purification and composition analysis of HPS[D]. Lanzhou: Lanzhou University, 23–30.

Mao, X., and Wang, F. (1989). Immunomodulatory effect of HPS and Astragalus polysaccharides[J]. China Pharmacol. Bull. 5 (6), 367–372.

Matoba, K., Takeda, Y., Nagai, Y., Kawanami, D., Utsunomiya, K., and Nishimura, R. (2019). Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease. *Int. J. Mol. Sci.* 20 (14), 3393. doi:10.3390/ijms20143393

Ouyang, Y., and Yan, J. (2013). Study on determination method of HPS content[J]. Chin. Med. Mod. distance Educ. china 11 (20), 149–151.

Qi, X., Jin, Z., Chen, C., Guan, Y., Wang, Q., Yu, H., et al. (2015a). Effect of HPS on renal protection and PKC/TIMP-1 expression in early diabetic nephropathy db/db mice [J]. *China J. ofGerontology* 35 (18), 5053–5056.

Qi, X., Jin, Z., Guan, Y., Wei, Y., and Zhu, Z. (2015b). Study on the mechanism of HPS slowingdown the progression of diabetic nephropathy in mice[J]. *China J. Clin. Pharmacol.* 31 (7), 526–529.

Qiang, Z., Yan, W., Li, S., Wang, M., and Li, C. (2018). Research progress on chemical structure and activity of HPS and its derivatives[J]. *China J. New Drugs* 27 (19), 2271–2280.

Ru, Y., Jin, Z., Zhang, H., and Li, G. (2015). Effect of HPS on the expression of retinal vascular endothelial growth factor in db/db mice[J]. *J. Lanzhou Univ. Med. Ed.* 41 (4), 15–19.

Shamsdin, S. A., Mehrafshan, A., Mehrabani, D., and Rakei, S. M. (2019). Evaluation of VEGF, FGF and PDGF and serum levels of inflammatory cytokines in patients with glioma and meningioma in southern Iran. Asian Pac J. Cancer Prev. 20 (10), 2883–2890. doi:10.31557/APJCP.2019.20.10.2883

Shan, M., Gao, S. M., and Ye, Y. (2017). Effect of HPS on the levels of VEGF, PEDF and CRP in retina of streptozotocin-induced diabetic rats[J]. *Sichuan Tradit. Chin. Med.* 35 (11), 54–57.

Shang, H., Sun, W., Cheng, W., Duan, Y., and Sun, X. (2014). Effect of HPS on lipid metabolism and stearyl-CoA desaturase 1 gene expression in nonalcoholic fatty liver rats[J]. *China J. Traditional Chin. Med. Inf.* 21 (7), 47–49.

Shao, J., Du, L., Wu, G., Yang, Z., and Guo, M. (2017a). Comparative study on the immunomodulatory effect of four kinds of Chinese medicinal polysaccharides, such as *Hedysarum* rubrum, on the immunocompromised mouse model induced by cyclophosphamide[J]. *China J. Clin. Pharmacol.* 33 (21), 2175–2186.

Shao, J., Du, L., Wu, G., and Guo, M. (2017b). Comparative study on the immunomodulatory effects of four kinds of Chinese medicinal polysaccharides, such as Radix Hedysari, on the immunocompromised mouse model induced by cyclophosphamide[J]. *China J. Clin. Pharmacol.* 33 (21), 2175–2178.

Shao, J., Wu, G., Wang, Z., Du, L., Ren, Y., Guo, M., et al. (2018). Protective effect of HPS on brain injury in rats with focal cerebral ischemia and its influence on related metabolites[J]. *China J. Clin. Pharmacol.* 34 (4), 432–435.

Shi, S., Dong, D., Li, S., Wu, X., and Zhang, J. (2019). Comparative study of anti-aging effects of HPS and *Astragalus* polysaccharides on rats[J]. *Chin. J. Mod. Appl. Pharm.* 36 (16), 2024–2028.

Shuo, Y., Yu, S., Liu, X., Yu, J., Zhang, X., Lu, H., et al. (2019). HPS intervenes the expression of glycogen synthase 3- β in endotoxin-induced uveitis model and its mechanism of action [J]. *New Adv. Ophthalmol.* 39 (2), 123–128.

Siedlecki, J., Asani, B., Wertheimer, C., Hillenmayer, A., Ohlmann, A., Priglinger, C., et al. (2018). Combined VEGF/PDGF inhibition using axitinib induces aSMA expression and a pro-fibrotic phenotype in human pericytes. *Graefes Arch. Clin. Exp. Ophthalmol.* 256 (6), 1141–1149. doi:10.1007/s00417-018-3987-8

Sulaimon, A. K., Tosin, O. O., Boyenle, I., Lei, D., Lu, Q., Yin, X. M., et al. (2020). Ampk allostery: A therapeutic target for the management/treatment of diabetic nephropathy [J]. *Life Sci.* 261, 118–455.

Sun, Q., Zheng, Y., Su, J., and Huang, Z. (1994). Effect of HPS on cellular immunity ofmice-Anti-aging study of HPS[J]. J. Gansu Coll. Traditional Chin. Med. 11 (2), 41–44.

Sun, W. M., Wang, Y. P., Duan, Y. Q., Shang, H. X., and Cheng, W. D. (2014). Radix Hedysari polysaccharide suppresses lipid metabolism dysfunction in a rat model of non-alcoholic fatty liver disease via adenosine monophosphate-activated protein kinase pathway activation. *Mol. Med. Rep.* 10 (3), 1237–1244. doi:10.3892/mmr.2014. 2327

Tan, Y. (2010). Study on identification and polysaccharide extraction technology of Hedysarum chinense[D]. Lanzhou: Lanzhou University of Technology, 37-48.

Tian, H., Di Yan, O., Song, J., and Nan, X. (2015). Experimental study of antitumor effect of HPS on bladder cancer rats[J]. *Foreign Med. Antibiot.* 36 (1), 27–28.

Tokita, Y., Yuko, M., Kenju, S., Seiichi, T., Nobuyoshi, I., Masako, A., et al. (2017). Non-alcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men and women. *Intern. Med.* 56 (7), 763–771. doi:10.2169/internalmedicine. 56.7115

Vincent, A. M., Calabek, B., Roberts, L., and Feldman, E. L. (2013). Biology of diabetic neuropathy. *Handb. Clin. Neurol.* 115, 591–606. doi:10.1016/B978-0-444-52902-2. 00034-5

Wan, S. (2012). Effect of HPS on T lymphocyte subsets in rats with spleen deficiency [J]. *Chin. Med. Res.* 25 (11), 73–75.

Wang, D., Jin, Z., Zhang, H., Seo, R., and Gong, X. (2017). Growth of hollow cell spheroids in microbead templated chambers. *China J. Traditional Chin. Med. Inf.* 24 (4), 57–64. doi:10.1016/j.biomaterials.2017.07.031

Wang, L., Jin, Z., Ma, J., Wang, Z., and Wu, G. (2013). Effect of HPS on blood glucose, glucose tolerance and tumor necrosis factor- α levels in alloxan hyperglycemia animal model[J]. J. Gansu Coll. Traditional Chin. Med. 30 (06), 6–9.

Wang, X., Guo, M., Wang, Z., Li, J., Liu, Q., Kang, F., et al. (2018). Significant expansion and red-shifting of fluorescent protein chromophore determined through computational design and genetic code expansion. *China J. Appl. Physiology* 34 (3), 273–285. doi:10.1007/s41048-018-0073-z

Wang, X., and Liu, H. (2017). Effect of HPS-1 on oxidative stress of human lung adenocarcinoma A549 cells[J]. Chin. J. Respir. Crit. care Med. 16 (2), 127-131.

Wang, X., Wei, M., Kuukasjärvi, P., Laurikka, J., Rinne, T., Moilanen, E., et al. (2009). The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). *Scand. Cardiovasc. J.* 43 (1), 72–79. doi:10. 1080/14017430802180449

Wang, Y., Zhang, Y., Li, J., Li, X., Liu, Y., Su, E., et al. (2022). Effects of HPS, *Hedysarum* flavone and *Hedysarum* saponin on bleomycin-inducedpulmonary fibrosis in rats[J]. *Chin. Pat. Med.* 44 (02), 573–578.

Wei, D., Chen, t., Yan, M., Zhao, W., Li, F., Cheng, W., et al. (2015). Synthesis, characterization, antioxidant activity and neuroprotective effects of selenium polysaccharide from Radix hedysari. *Carbohydr. Polym.* 125, 161–168. doi:10.1016/j. carbpol.2015.02.029

Wei, S., Chen, F., Yan, Z., Jin, H., and Wang, J. (2014). Optimization of enzymatic extraction technology of HPS and saponins by quadratic general rotation combination design[J]. *Chin. Pat. Med.* 36 (2).

Wei, S., Wang, J., Li, C., Jin, H., and Zhang, W. (2013). Study on the method of determining crude polysaccharide of *Hedysarum* rubrum by improved differential phenol-sulfur method[J]. *Chin. Pat. Med.* 35 (3), 634–636.

Wei, Y., Wang, Q., Cui, F., Liu, D., Deng, Y., Wang, X., et al. (2011). Effect of HPS on hematogenous metastasis of hepatocellular carcinoma cells[J]. *Med. Inf. Zhong Xun J.* 24 (8), 3559–3560.

Wu, X., Liu, Y., Guo, X., Zhou, W., Wang, L., Shi, J., et al. (2018). Prolactin inhibits the progression of intervertebral discdegeneration through inactivation of the NF- κ B pathway in rats. *Cell Death Dis.* 9 (2), 98. doi:10.1038/s41419-017-0151-z

Xie, J., Li, B., Zhang, P., Wang, L., Lu, H., and Song, X. (2018). Osteogenic protein-1 attenuates the inflammatory cytokine-induced NP cell senescence through regulating the ROS/NF-κB pathway. *Biomed. Pharmacother.* 99 (99), 431–437. doi:10.1016/j. biopha.2018.01.053

Xie, S. G., and Meng, K. (2018). Research progress of aging mechanism and anti-aging ofMongolian medicine[J]. *China Ethn. Folk Med.* 27 (11), 50–52.

Xu, J. (2009). Hypoglycemic effect of HPS-3 on experimental type I diabetic mice[D]. Lanzhou, China: Lanzhou University.

Yan, C., Li, Q., Yao, Z., and Liu, Y. (2017). Effects of HPS on immune function and cytokines in immunosuppressed rats[J]. *China J. Clin. Pharmacol.* 33 (13), 1233–1236.

Yang, H., and Li, S. (2013). Extraction, separation and content determination of HPS [J]. Anhui Agric. Sci. 41 (25), 10278–10332.

Yang, J., Wei, D., Li, X., Zhang, Z., and Lv, X. (2016). Study on the difference of protective effect of HPS on oxidative damage of brain microvascular endothelial cells in protein[J]. *Pharmacol. Clin. Traditional Chin. Med.* 32 (2), 113–118.

Yang, T. (2014). Extraction and isolation of Hedysarum polysaccharide HPS and study on the structural characteristics and anti-complement activity of four components of HPS1[D]. Lanzhou: Lanzhou University, 31.

Yang, T., Guo, L., Li, C., Yang, Y. L., and Feng, S. L. (2014a). Chemical structural features and anti-complementary activity of polysaccharide HPS1-D from Hedysarum polybotrys. *China J. Traditional Chin. Med.* 39 (1), 89–93.

Yang, T., Guo, L., Li, C., Yang, Y. L., and Feng, S. L. (2014b). Study on the chemical structure and anticomplement activity of *Hedysarum* polysaccharide HPS1-D[J]. *Chin. J. Traditional Chin. Med.* **39** (1), 89–93.

Yang, X., Xue, Z., Fang, Y., Liu, X., Yang, Y., Shi, G., et al. (2019). Structure-immunomodulatory activity relationships of *Hedysarum* polysaccharides extracted by a method involving a complex enzyme combined with ultrasonication[J]. *Food Funct.* 10 (2), 1146–1158. doi:10.1039/c8fo02293c

Ye, W., Gong, Z., He, Y., Chen, Y., Zhao, Q., and Zhou, Z. (2020). Effects of active polysaccharides from processing wastes of Wendang and *Hedysarum* rubrum on blood glucose and blood lipid of type II diabetic mice[J]. *J. Gansu Agric. Univ.* 55 (2), 32–39.

Yu, X., Guo, M., and Shao, J. (2005). Determination of polysaccharide content in six kinds of *Hedysarum* from Gansu[J]. *Mod. Tradit. Chin. Med.* 25 (6), 45–46.

Yuan, J., Wang, Y., and Huang, Y. (2019). Study on microwave extraction technology of HPS and its antioxidant activity[J]. *Appl. Chem. Eng.* 48 (2), 373–375.

Yuan, J., Yu, X., Huang, Y., and Wang, Y. (2015). Optimization of extraction process of HPS by multi-index orthogonal test[J]. *Appl. Chem. Eng.* 44 (11), 2162–2164.

Zeng, S., Peng, B., Cheng, W., Wei, D., Huang, W., Li, Y., et al. (2019). Experimental study on the effect of HPS and HPS selenide on oral cancer cells *in vitro*[J]. *Oral Dis. Prev.* 27 (12), 757–762.

Zhang, H. (2018). Changes of TSP-1 and PDGF-B expression in retina of diabetic rats and intervention of HPS. China: Gansu Province, Gansu University of Traditional Chinese Medicine.

Zhang, H., Jin, Z., Liu, Y., Liu, S. Q., Shi, P. Y., Qin, C. F., et al. (2017a). Generation and characterization of West Nile pseudo-infectious reporter virus for antiviral screening. *China J. Traditional Chin. Med. Inf.* 24 (3), 38–47. doi:10.1016/j.antiviral.2017.02.006

Zhang, H., Jin, Z., Wang, D., et al. (2017b). Effect of HPS on myocardial fibrosis of diabetic cardiomyopathy in db/db mice[J]. China J. Clin. Pharmacol. 33 (3), 239-243.

Zhang, H., Liu, Y., Li, G., Wang, H., Jin, W., Wen, J., et al. (2016). Role of plant MicroRNA in cross-species regulatory networks of humans. *Chin. Med. Res.* 29 (2), 60–63. doi:10.1186/s12918-016-0292-1

Zhang, G., Zhou, S., Yan, Y., Guo, M., and Wang, Z. (2019). Therapeutic effect of *Hedysarum* heteropolysaccharide and its hyaluronic acid hydrogel on osteoarthritis in rats[J]. *J. Immunol.* 35 (1), 65–70.

Zhao, B., Kou, N., Wang, Y., and Feng, L. (2015). Microwave-assisted extraction of HPS[J]. *Food Ferment. Industry* 41 (11), 228–235.

Zhao, J., and Liu, Y. (2016). Effect of HPS on nuclear transcription factor-kb238 in early retina of diabetic rats. Pharmacology and clinic of traditional Chinese medicine 2020; 36(6 randomized parallel controlled study of influence). J. Pract. Traditional Chin. Intern. Med. 30 (4), 77–81.

Zhao, L., Chen, T., Feng, D., Xiao, T. G., Dang, Z. L., Feng, S. L., et al. (2014). Structural characterization and antioxidant activity of a heteropolysaccharide isolated from *Hedysarum* polybotrys[J]. *J. Asian Nat. Prod. Res.* 16 (6), 677–684. doi:10.1080/ 10286020.2014.893512

Zhao, L., Li, X., Zhao, J., Hu, F., Feng, S., and Liu, J. (2009). Effects of four HPS on blood glucose in experimental diabetic mice[J]. *Chin. Herb. Med.* 32 (10), 1590–1592.

Zhao, Y., Chen, J., Xu, J., and Zhang, T. (2015). Research progress of chemical constituents and antitumor effects of *Hedysarum* rubrum[J]. *Chin. Herb. Med.* 46 (22), 3434–3440.

Zhou, J., Zhang, L., Zheng, B., Qin, Y., Zhang, X., Yang, Z., et al. (2020). Salvia miltiorrhiza bunge exerts anti-oxidative effects through inhibiting KLF10 expression in vascular smooth muscle cells exposed to high glucose. *J. Ethnopharmacol.* 262, 113208. doi:10.1016/j.jep.2020.113208